Sugen Incorporated

Monsanto Technology LLC

Pfizer Corporation

G Davis Harris, Jr

Peng Cho Tang

Terri L Boehm

Daniel Patrick Walker

Jeffery N Carroll

Justin Robert Struble

Matthew D McReynolds

Mangesh Bore

Gerald McMahon

Jennifer R Zhang

Jingrong Jean Cui

Congxin Liang

Cathleen Elizabeth Hanau

Ping Huang

Lei Jia

Pei-Pei Kung

Dilip Ramakant Bhumralkar

Mitchell David Nambu

Mason Alan Pairish

Hong Shen

Huiping Guan

Iriny Botrous

Connie Li Sun

Michelle Bich Tran-Dube

Fang-Jie Zhang

Jerry Jialun Meng

Stephen A Kolodziej

Lee Andrew Funk

Ji Yu Chu

Joanne Johnson

Xiaoyuan (Sharon) Li

Jason (Qishen) Lin

Christopher G Nelson

Allison Walter

John Yudhistir Ramphal

Asaad S Nematalla

The present disclosure relates, in general, to 5-halo-3,6-dichlorosalicylic acid compounds, 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 5-halo-3,6-dichlorosalicylic acid compounds, processes for preparing 5-halo-3,6-dichlorosalicyaldehyde compounds, processes for preparing 3,6-dichlorosalicylic acid compounds, and processes that employ such compounds as intermediates in the preparation of the herbicide dicamba.

3,6-dichlorosalicylic acid compounds and related synthetic processes

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET. 

Aminoheteroaryl compounds as protein kinase inhibitors

Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET 

The present invention relates to substituted imidazopyrazines of the general Formula I which modulate the activity of protein kinases ('PKs'). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors

The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases ('PKs'). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

The present invention relates to novel synthetic methods for the preparation of indolylquinones. The methods of the present invention are directed to synthetic reactions involving indoles and halo-quinones in solvent and in the presence of a metal carbonate. The invention also relates to bis- and mono-indolylquinones of high purity and pharmaceutical compositions containing the same.

Synthetic methods for the preparation of indolylquinones and mono- and

The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of complexing with a member of the SH2- and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.

Methods and compositions for inhibition of adaptor protein/tyrosine

The present invention relates to thiazole containing compounds capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such compounds to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such compounds to treat various disease states including diabetes mellitus.

Thiazole compounds and methods of modulating signal transduction

Synthetic methods for the preparation of indolyquinones

The present invention relates to methods and compositions for the inhibition of adaptor protein/protein tyrosine kinase protein interactions, especially wherein those interactions involving a protein tyrosine kinase capable of completing with a member of the SH2- and/or SH3-containing family of adaptor proteins are associated with a cell proliferative disorder. Specifically, the present invention relates to particular compounds, especially quinazoline derivative compounds, and methods utilizing such compounds.

Method and compositions for inhibition of adaptor protein/tyrosine

Growing community of inventors

Chesterfield, MO, United States of America

G Davis Harris, Jr